Barclays’s Immunic IMUX Stock Holding History

Barclays’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-158	Closed	-$17K	–	7111
2018 Q3	$17K	Buy	+158	New	+$412K	﹤0.01%	6510

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Barclays's IMUX Position: Q2 2026 in Review

Barclays increased its Immunic (IMUX) stake by 103% in Q2 2026, buying an estimated $3.1K and bringing the position to 494 shares worth $7.59K. The position accounts for ﹤0.01% of the portfolio, ranked #4733.

Barclays first reported a position in IMUX in Q2 2014 and has held it in 32 quarters since. The position peaked at $217K in Q4 2021. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

Barclays held 494 shares of Immunic worth $7.59K as of Q2 2026.
Barclays bought 251 Immunic shares in Q2 2026, an estimated $3.1K.
Immunic made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4733 holding.
Barclays first reported a position in Immunic in Q2 2014 and has held it in 32 quarters since.
Barclays's Immunic position peaked at $217K in Q4 2021.
55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.